FGF-16 is a target for adrenergic stimulation through NF-B activation in postnatal cardiac cells and adult mouse heart

Alina G. Sofronescu, Karen A. Detillieux, Peter A. Cattini

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aims The fibroblast growth factor (FGF) family plays an important role in cardiac growth and development. However, only FGF-16 RNA levels are reported to increase during the perinatal period and to be expressed preferentially in the myocardium, suggesting control at the transcriptional level and a role for FGF-16 in the postnatal heart. Beyond the identification of two TATA-like elements (TATA1 and TATA2) in the mouse FGF-16 promoter region and the preferential cardiac activity of TATA2, there is no report of Fgf-16 gene regulation. Assessment of promoter sequences, however, reveals putative nuclear factor-kappaB (NF-κB) elements, suggesting that Fgf-16 is regulated via NF-κB activation and thereby implicated in a number of cardiac events. Thus, the Fgf-16 gene was investigated as a target for NF-κB activation in cardiac cells. Methods and resultsAssessments of Fgf-16 promoter activity were made using truncated and transfected hybrid genes with NF-κB inhibitors and/or-adrenergic stimulation via isoproterenol (IsP) treatment (a known NF-κB activator) in culture, and on endogenous mouse and human Fgf-16 genes in situ. The mouse Fgf-16 promoter region was stimulated in response to IsP treatment, but this response was lost with NF-κB inhibitor pretreatment. Deletion analysis revealed IsP responsiveness linked to sequences between TATA2 and TATA1 and, more specifically, a NF-κB element upstream and adjacent to TATA1 that associates with NF-κB p50/p65 subunits in chromatin. Finally, TATA1 and the proximal NF-κB element are conserved in the human genome and responsive to IsP. Conclusion The mouse and human Fgf-16 gene is a target for NF-κB activation in the postnatal heart.

Original languageEnglish (US)
Pages (from-to)102-110
Number of pages9
JournalCardiovascular research
Volume87
Issue number1
DOIs
StatePublished - Jul 1 2010

Fingerprint

Fibroblast Growth Factors
Adrenergic Agents
Isoproterenol
Genes
Genetic Promoter Regions
Human Genome
Growth and Development
Chromatin
Myocardium
RNA

Keywords

  • FGF-16
  • Gene regulation
  • Isoproterenol
  • Mouse and human heart
  • Nuclear factor-kappaB

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

FGF-16 is a target for adrenergic stimulation through NF-B activation in postnatal cardiac cells and adult mouse heart. / Sofronescu, Alina G.; Detillieux, Karen A.; Cattini, Peter A.

In: Cardiovascular research, Vol. 87, No. 1, 01.07.2010, p. 102-110.

Research output: Contribution to journalArticle

@article{12a00bb4234745ed947eac943787563c,
title = "FGF-16 is a target for adrenergic stimulation through NF-B activation in postnatal cardiac cells and adult mouse heart",
abstract = "Aims The fibroblast growth factor (FGF) family plays an important role in cardiac growth and development. However, only FGF-16 RNA levels are reported to increase during the perinatal period and to be expressed preferentially in the myocardium, suggesting control at the transcriptional level and a role for FGF-16 in the postnatal heart. Beyond the identification of two TATA-like elements (TATA1 and TATA2) in the mouse FGF-16 promoter region and the preferential cardiac activity of TATA2, there is no report of Fgf-16 gene regulation. Assessment of promoter sequences, however, reveals putative nuclear factor-kappaB (NF-κB) elements, suggesting that Fgf-16 is regulated via NF-κB activation and thereby implicated in a number of cardiac events. Thus, the Fgf-16 gene was investigated as a target for NF-κB activation in cardiac cells. Methods and resultsAssessments of Fgf-16 promoter activity were made using truncated and transfected hybrid genes with NF-κB inhibitors and/or-adrenergic stimulation via isoproterenol (IsP) treatment (a known NF-κB activator) in culture, and on endogenous mouse and human Fgf-16 genes in situ. The mouse Fgf-16 promoter region was stimulated in response to IsP treatment, but this response was lost with NF-κB inhibitor pretreatment. Deletion analysis revealed IsP responsiveness linked to sequences between TATA2 and TATA1 and, more specifically, a NF-κB element upstream and adjacent to TATA1 that associates with NF-κB p50/p65 subunits in chromatin. Finally, TATA1 and the proximal NF-κB element are conserved in the human genome and responsive to IsP. Conclusion The mouse and human Fgf-16 gene is a target for NF-κB activation in the postnatal heart.",
keywords = "FGF-16, Gene regulation, Isoproterenol, Mouse and human heart, Nuclear factor-kappaB",
author = "Sofronescu, {Alina G.} and Detillieux, {Karen A.} and Cattini, {Peter A.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1093/cvr/cvq025",
language = "English (US)",
volume = "87",
pages = "102--110",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - FGF-16 is a target for adrenergic stimulation through NF-B activation in postnatal cardiac cells and adult mouse heart

AU - Sofronescu, Alina G.

AU - Detillieux, Karen A.

AU - Cattini, Peter A.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Aims The fibroblast growth factor (FGF) family plays an important role in cardiac growth and development. However, only FGF-16 RNA levels are reported to increase during the perinatal period and to be expressed preferentially in the myocardium, suggesting control at the transcriptional level and a role for FGF-16 in the postnatal heart. Beyond the identification of two TATA-like elements (TATA1 and TATA2) in the mouse FGF-16 promoter region and the preferential cardiac activity of TATA2, there is no report of Fgf-16 gene regulation. Assessment of promoter sequences, however, reveals putative nuclear factor-kappaB (NF-κB) elements, suggesting that Fgf-16 is regulated via NF-κB activation and thereby implicated in a number of cardiac events. Thus, the Fgf-16 gene was investigated as a target for NF-κB activation in cardiac cells. Methods and resultsAssessments of Fgf-16 promoter activity were made using truncated and transfected hybrid genes with NF-κB inhibitors and/or-adrenergic stimulation via isoproterenol (IsP) treatment (a known NF-κB activator) in culture, and on endogenous mouse and human Fgf-16 genes in situ. The mouse Fgf-16 promoter region was stimulated in response to IsP treatment, but this response was lost with NF-κB inhibitor pretreatment. Deletion analysis revealed IsP responsiveness linked to sequences between TATA2 and TATA1 and, more specifically, a NF-κB element upstream and adjacent to TATA1 that associates with NF-κB p50/p65 subunits in chromatin. Finally, TATA1 and the proximal NF-κB element are conserved in the human genome and responsive to IsP. Conclusion The mouse and human Fgf-16 gene is a target for NF-κB activation in the postnatal heart.

AB - Aims The fibroblast growth factor (FGF) family plays an important role in cardiac growth and development. However, only FGF-16 RNA levels are reported to increase during the perinatal period and to be expressed preferentially in the myocardium, suggesting control at the transcriptional level and a role for FGF-16 in the postnatal heart. Beyond the identification of two TATA-like elements (TATA1 and TATA2) in the mouse FGF-16 promoter region and the preferential cardiac activity of TATA2, there is no report of Fgf-16 gene regulation. Assessment of promoter sequences, however, reveals putative nuclear factor-kappaB (NF-κB) elements, suggesting that Fgf-16 is regulated via NF-κB activation and thereby implicated in a number of cardiac events. Thus, the Fgf-16 gene was investigated as a target for NF-κB activation in cardiac cells. Methods and resultsAssessments of Fgf-16 promoter activity were made using truncated and transfected hybrid genes with NF-κB inhibitors and/or-adrenergic stimulation via isoproterenol (IsP) treatment (a known NF-κB activator) in culture, and on endogenous mouse and human Fgf-16 genes in situ. The mouse Fgf-16 promoter region was stimulated in response to IsP treatment, but this response was lost with NF-κB inhibitor pretreatment. Deletion analysis revealed IsP responsiveness linked to sequences between TATA2 and TATA1 and, more specifically, a NF-κB element upstream and adjacent to TATA1 that associates with NF-κB p50/p65 subunits in chromatin. Finally, TATA1 and the proximal NF-κB element are conserved in the human genome and responsive to IsP. Conclusion The mouse and human Fgf-16 gene is a target for NF-κB activation in the postnatal heart.

KW - FGF-16

KW - Gene regulation

KW - Isoproterenol

KW - Mouse and human heart

KW - Nuclear factor-kappaB

UR - http://www.scopus.com/inward/record.url?scp=77955161546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955161546&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvq025

DO - 10.1093/cvr/cvq025

M3 - Article

C2 - 20097674

AN - SCOPUS:77955161546

VL - 87

SP - 102

EP - 110

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -